Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil

Transplant International

Volumn 17, Issue 10, 2004, Pages 609-616

  Hardinger, Karen L ^a   Brennan, Daniel C ^b   Lowell, Jeffrey ^b   Schnitzler, Mark A ^b,c  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost; Gastrointestinal complications; Graft survival; Immunosuppression; Kidney transplantation; Post transplant complications

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; GRAFT SURVIVAL; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 12144273473     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.tb00394.x     Document Type: Article

References (23)

1. Helderman JH. Prophylaxis and treatment of gastrointestinal complications following transplantation. Clin Transplant 2001; 15:29.
2. Rubin RH. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities. Clin Transplant 2001; 15:11.
3. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13:277.
4. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47:215.
5. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Aetiology, incidence and management. Drug Saf 2001; 24:645.
6. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225.
7. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321.
8. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection on cadaveric renal transplantation. Transplantation 1996; 61:1029.
9. Pescovitz MD, Navarro MT. Immunosuppressive therapy and post-transplantation diarrhea. Clin Transplant 2001; 15:23.
10. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Transplantation 2003; 17:2000.
11. United States Renal Data System. Researcher's guide to the USRDS database. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md; 1998.
12. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transpl 2003; 3:178.
13. Port F, Bragg-Gresham JL, Metzger R, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 2002; 74:1281.
14. Woodward RS, Schnitzler MA, Baty J, et al. The incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transpl 2003; 3:590.
15. Schnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transpl 2003; 3:445.
16. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34:429.
17. Mourad M, Malaise J, Eddour DC, et al. Correlation of mycophenolate acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47:88.
18. Van Gelder T, Hillbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68:261.
19. Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64:672.
20. Guerard A, Rabodonirina M, Cotte L, et al. Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999; 68:699.
21. Sarmiento JM, Dockrell DH, Schwab TR, et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14:136.
22. Kaplan B, Meier-Kriesche HU, et al. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplantation recipients with persistent abdominal pain. Am J Kidney Dis 1999; 34:65.
23. Schnitzler MA. Diabetes mellitus after kidney transplantation in the United States (letter). Am J Transpl 2003; 3:1381.